Up to date, IGLUCIOT secured pre-sales orders with projected revenue of €3M to €5M (€163k net burn) in the first 18 months while reaching €72M in revenue year 3.
IGLUCIOT will be serving pre-diabetics and health-consciousness individuals in EU, US and Asia markets and B2B customers mainly in the consumer electronics and online pharmacies sector with a target of up to 2M+ clients in 3 years.
IGLUCIOT is now looking to raise €2M seed funding. The ideal investor would have interest in the digital healthcare, consumer electronics sector, Sales and Marketing in EU, US
and Asian countries. The investment is needed to: Finalize the product USP and close additional pre-sales deals of 10K-20K units with projected revenue of €3M-€5M by December 2026.
Piloting to manufacture the first batch, planning to secure more business partnerships with consumer electronics companies like Elgiganten and Telia and other suppliers and
distributors such as Newgen distribution and Tura.
Kick start a marketing campaign, scale mass production and delivery of 25K units to B2C consumers by Q1 2027 with projected revenue of €6M. With a conversion target of 5M+ diabetes patients in the US and EU,
IGLUCIOT is poised to capture within the next 5 years a 2% to 7% of shares (€1.5Bn) of the global diabetes market worth €132Bn (+4.2% CAGR). Based on industry comparable (e.g. Omada Health / IPO for €1.28B on June 6, 2025),
IGLUCIOT is seeking to exit in 2031 via IPO or acquisition by similar global leading companies such as Teladoc, at a post-money valuation of €1.4Bn (245x+ ROI) and potential upside exceeding €1.5Bn.
